Although transcriptional activation of PTEN is yet to be achieved in vivo, CRISPR/Cas9-mediated repression of PTEN in mouse models has demonstrated the ability of this system to target PTEN in vivo to rapidly induce PTEN-deficient murine liver disease and mammary tumors [135,136,137]. The gene discussed is PTEN; the disease is breast cancer.